PATENT CLAIM ANALYSIS

Application Number: 16239806
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-04
Patent Classification: ["514", "007700"]

Abstract:
A method for inhibiting renal hypofunction in a non-human animal includes administering cat-derived erythropoietin to the non-human animal. The non-human animal may have renal hypofunction. The non-human animal may have chronic kidney disease and the renal hypofunction may be caused by the chronic kidney disease. The cat-derived erythropoietin may be administered repeatedly at a time interval of 7 to 30 days.

Claim (Index 10):
The method according to  claim 1 , wherein the cat-derived erythropoietin comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, and a variant amino acid sequence derived from SEQ ID NO: 2 or SEQ ID NO: 3.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 99.0
- Lexical Diversity: 1.80556
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14945283', '15218784', '13661668', '12617721', '12618338']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7818960739734693
- 35 USC 102 Novelty (BERT): 0.5165570155586373
- Combined Prediction Score: 0.7553621681319861
- Mean Citation Score: 223.976366
- Max Citation Score: 233.09639
- Similarity Product: 121.04985536054552

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test